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intrOductiOn
Cardiovascular disease and its complications is the
major cause of the augmented morbidity and mortality
that characterizes patients suffering from chronic kid-
ney disease (CKD) (1). According to Go et al cardio-
vascular risk elevates as renal function declines and
is dramatically high in patients with end stage renal
disease (ESRD) (2). Indeed, CKD patients are more
likely to die from cardiovascular disease than to reach
ESRD and undergo dialysis (3). In 1998, the USRDS
(United States Renal Data System) reported that car-
diovascular disease was responsible for 40-50% of
death causes in ESRD patients and that its prevalence
was 10 to 20 times higher than in the general popu-
lation even after adjustment for age, sex, race and di-
abetes mellitus (4). 
Traditional and non-traditional, urea related, risk
factors have been described in an attempt to explain
the augmented cardiovascular morbidity and mortality
(5). Over the past few years, newer risk factors have
emerged and nephrologists have focused on the role
that inflammation and oxidative stress play in ESRD
patients (6). Obstructive sleep apnea syndrome
(OSAS) is an established cardiovascular risk factor
in the general population that lately has been included
among the newer risk factors in ESRD patients, as
well (5-7). It is reported that in this population its
prevalence is over 50% (8). The extremely high preva-
lence of the syndrome and its relation to the augment-
ed cardiovascular morbidity and mortality makes its
understanding and recognition a necessity for the
nephrologist. 
definitiOn And epidemiOlOgy
OSAS is characterized by repeated episodes of partial
or complete obstruction of upper airway during sleep
(9). The full-blown syndrome includes many different
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symptoms, with excessive daytime sleepiness, loud s-
noring and non-refreshing sleep being the most com-
mon ones. In many cases, choking during sleep, wit-
nessed apneas, morning headaches, as well as, nocturia
and decreased libido are described. Additionally,
symptoms related to sleep deprivation, such as de-
creased concentration, memory loss and irritability,
are included. Clinically, the diagnosis of OSAS is es-
tablished when at least 5 obstructive episodes (apneas,
hypopneas or respiratory effort related arousals) are
recorded, combined with daytime sleepiness, loud s-
noring, witnessed breathing interruptions or awak-
enings due to gasping or choking. 
In the general population it is estimated that 9%
of women and 24% of men have Apnea Hypopnea
Index (AHI) ≥5 episodes per hour of sleep and that
2% of women and 4% of men meet the minimal cri-
teria for the diagnosis of OSAS (10). In 2002, Young
et al, reported that one of 5 adults with Body Mass
Index (BMI) 25-28kg/m2 suffers from at least mild
OSAS and that one of 15 from at least moderate syn-
drome (11). Already in 1982 the first study related to
sleep problems in hemodialysis patients was published
(12). According to this study 14 out of the 22 patients
that participated referred reduced and fragmented
sleep. Since then many studies were conducted in ES-
RD patients and it is estimated that the prevalence
of the syndrome, as already mentioned, is over 50%
and is surprisingly high in this population. Indeed,
this high prevalence concerns ESRD patients on
hemodialysis, on peritoneal dialysis and transplanted
patients, as well (8). 
Unfortunately, the majority of the studies con-
ducted in this field have severe limitations (13). More
precisely, the diagnosis of OSAS in many studies is
based on the results of the Berlin Questionnaire and
the Epworth Scale (14, 15). Both of those question-
naires are considered to be reliable for the diagnosis
of the syndrome in the general population but have
not been yet validated in patients suffering from CKD.
In any case, it must be highlighted that the gold stan-
dard for OSAS’s diagnosis is a full polysomnography
study (9). Moreover, in many studies there was a se-
lection bias, as patient selection was based only on
the presence or absence of clinical symptoms indicative
of OSAS. Finally, one more significant limitation that
must be mentioned is the presence of different co-
morbidities, beyond CKD, that could predispose to
OSAS, such as cardiovascular diseases, diabetes mel-
litus and obesity (14). Even though all of those limi-
tations plus the small sample size could not be over-
looked, still it is clear that the prevalence of the syn-
drome in CKD patients is extremely high (15). 
Unruh et al, in an attempt to overcome the afore-
mentioned limitations, randomly selected ESRD pa-
tients undergoing hemodialysis 3 times per week and
compared them to a group of patients selected from
the ones that participated in the Sleep Heart Health
Study (13). More precisely, 46 elderly hemodialysis
patients were compared to 137 patients of the Sleep
Heart Health Study matched for age, sex, BMI and
race. According to the results of the study, the preva-
lence of OSAS was 4 times higher in the group of
hemodialysis patients. Moreover, hemodialysis patients
presented more severe hypoxia during sleep, shorter
sleep duration and greater sleep fragmentation than
the controls. 
The prevalence of OSAS seems to be augmented
not only in ESRD patients undergoing hemodialysis
but in patients with milder degree of CKD, as well
(15). Markou et al found that 54.3% of patients with
glomerular filtration rate (GFR) <40ml/min that did
not undergo hemodialysis suffer from OSAS and that
in those patients AHI correlated negatively with GFR
(16). Roumelioti et al confirmed the augmented preva-
lence of the syndrome in patients with mild degree
of CKD (17), while Agrawal et al published that in
obese patients the severity of OSAS correlates posi-
tively with serum creatinine elevation (18) and Sak-
aguchi et al that there is a negative correlation between
AHI and GFR (19). In the latter study, participated
100 patients with GFR <89ml/min and it was found
that the prevalence of OSAS in this population was
65% and that there was a 42% elevation of this preva-
lence for every 10ml/min reduction of GFR, even after
adjusting for age, BMI and diabetes mellitus. 
risk fActOrs
In the general population the prevalence of OSAS is
closely related to sex, age and ethnicity. It is known
that the prevalence of the syndrome is 2 to 3 times
higher in men than in women and its severity is worst
in men compared to women of the same age (20).
Furthermore, the prevalence is higher in post than
pre menopause women or post menopause women
receiving hormonal replacement therapy (20). It is
believed that hormonal, structural and factional dif-
ferences between the two sexes could explain this ob-
servation (21). One the other hand, the prevalence
of OSAS elevates in co-ordinance to the age of the
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patients and reaches its peak levels between the ages
of 50 and 60, while it seems to decrease in the elderly
ones (10). Probably the elderly patients that live alone
or suffer from hearing loss cannot provide a detailed
history in order to diagnose accurately the syndrome
(22). Another explanation focuses on natural selection
and the survival of the elderly ones that do not suffer
from OSAS (22). Finally, race seems to be related to
the risk and the severity of OSAS, a correlation at-
tributed to obesity, differences in social and econom-
ical status and environmental factors (21). 
The most important risk factor for OSAS in the
general population is obesity (10). It is believed that
even small augmentation of body weight could result
in augmentation of the risk for OSAS. Moreover, it
is believed that obesity correlates not only with the
presence of the syndrome but with its rapid rate of
progression, as well (23). The narrow upper airway is
another very important risk factor for the development
of the syndrome. More precisely, obesity, tonsilar and
tongue hypertrophy, enlarged uvula, retrognathia or
even family predisposition are considered factors that
could reduce the size of the pharynx and lead to OSAS
occurrence (24). One the other hand, alcohol con-
sumption and smoking play fundamental role on the
development of the syndrome (11). It seems that al-
cohol consumption before sleep correlates negatively
with the patency of the upper airway, while smoking
could deteriorate OSAS and even more its cessation
could reverse the syndrome.  
Although it is obvious that age, male sex and obe-
sity play fundamental role in the occurrence of OSAS
in the general population, when it comes to CKD pa-
tients the risk factors of OSAS are not fully under-
stood. Indeed, in many studies the risk factors of this
specific population present great differences to the
ones of the general population (8, 14, 25, 26) and the
correlation of OSAS with age, sex and obesity present
controversial results (27, 28). One possible explanation
in this discrepancy is the weakness of the studies al-
ready conducted in the field to reveal strong correla-
tions, though the sample of CKD patients was in most
cases quite small (14). Another possibly explanation
is that this controversy could be attributed to special
characteristics and conditions of the sample that result
from CKD itself (25). Regarding BMI, its correlation
with OSAS occurrence is not always strong and in
many cases the OSAS patients with ESRD are not as
obese as the ones in the general population. It is pro-
posed that in this population it is not BMI that leads
to the high prevalence of OSAS but the fact that BMI
may reflect fluid overload or even high levels of uremic
toxins. One the other hand, the prevalence of both
CKD and OSAS increases as the age of the population
increases. So the likelihood of suffering from both as
the age increases is high. Finally, it is known that after
menopause the prevalence of OSAS in women in the
general population increases. In CKD patients many
hormonal changes take place and women usually have
anovulation and amenorrhea that diminish the ex-
pected differences that characterize sexes.
Clinical presentation of OSAS in CKD patients
seems to be unique, as well. Loud snoring, witnessed
episodes of apneas during sleep and morning
headaches are not considered reliable clinical criteria
in order to diagnose OSAS in ESRD patients under-
going dialysis (29). Snoring seems to be less common
and less loud in this population than in the general
population. Furthermore, partners of ESRD patients
with OSAS do not report as usual episodes of apneas
during sleep. One the other hand, many of the clinical
symptoms that characterize OSAS patients, such as
daytime somnolence, fatigue, depression, mental and
sexual dysfunction are symptoms closely related to
uremia itself (25, 26). The altered clinical presentation
of the syndrome in ESRD patients and the common
symptoms between OSAS and uremia make its diag-
nosis quite a challenge for a nephrologist. 
pAthOphysiOlOgy
Pharynx is a complex structure that maintains its func-
tion thanks to the balance of opposite forces of dilation
and collapse (24). Any disruption of this balance
during sleep could lead to obstruction episodes such
as the ones described in patients suffering from OSAS,
although during day dilation muscles, especially ge-
nioglossus, seem to dominate and preserve the upper
airway patency. The anatomic structure of pharynx
and factors such as obesity, tonsilar and tongue hy-
pertrophy, enlarged uvula, retrognathia that have
been already mentioned seem to play key role in its
predisposition to collapse during sleep. In OSAS pa-
tients, to these mechanical problems that lead to an
easier collapse of the pharynx one must add the altered
function of the dilation muscles. The inflammation
and denervation of the dilation muscles resulting from
vibration during snoring could disrupt their function
during sleep (30). At the same time the ventilation
instability described in OSAS patients jeopardize the
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upper airway patency (31). Finally, the translocation
of water from the lower extremities to upper body
during sleep leads to augmentation of the neck circum -
ference and predisposes to obstruction, as well (32). 
Regarding ESRD patients it seems that the high
prevalence of OSAS is the result of the combined ef-
fect of many different factors that characterize this
unique population. Uremia and uremic toxins,
hypocapnia due to metabolic acidosis, oedema of the
upper airway due to fluid overload, reduced muscle
tone and neuropathy of the autonomic nervous system
are some of the factors believed to play an important
role and explain this high prevalence (8, 14, 15, 25,
26, 33). Furthermore, anemia, cardiovascular disease
and other comorbidities that are usually found in ES-
RD patients, use of specific medicines, such as seda-
tives, pain killers and some antihypertensives, psy-
chological factors and special factors reflecting the
way of life of those patients are believed to play im-
portant role, as well. Finally, the role of the augmented
levels of many different cytokines that are described
in ERSD patients and are believed to be closely related
to the occurrence of sleep disturbances must be men-
tioned (34). 
Beecroft et al described in ERSD patients many
significant alternations of the sensitivity of the respi-
ratory center and the central and peripheral chemore-
ceptors. Indeed, they found enhanced responsiveness
to hypercapnia of both central and peripheral
chemoreceptors that control the respiratory drive.
Those changes are believed to result from uremia and
hypopnea due to metabolic acidosis of CKD. Some
years later the same researchers published a study
that confirmed their past results and surprisingly
demonstrated reduction of chemoreceptors hyper-
sensitivity and reduction of the severity of the syn-
drome in ESRD patients that instead of daytime
hemodialysis during the study underwent nocturnal
hemodialysis (29).
Oedema of the upper airway due to fluid overload,
as has already been mentioned, is one of the factors
responsible for OSAS pathogenesis in ESRD. There
is evidence supporting that the pharynx of CKD pa-
tients is narrower than in the general population (35).
One the other hand, it is believed that during the
nighttime sleep fluid is transferred from the lower ex-
tremities to the neck, resulting in augmentation of its
circumference and in augmentation of the duration
of the obstructive episodes (36). In a recent published
study the authors report that the fluid overload and
its translocation during sleep are related to augmen-
tation of the jugular volume and oedema of the upper
airway mucosal (37). The role of the oedema in the
pathogenesis of the syndrome in ESRD patients is
highlighted by the findings of Beecroft et al (38). The
authors found that the size of the pharynx increases
after initiation of nocturnal instead of daytime
hemodialysis. The same results were found in peri-
toneal dialysis patients. More precisely, the authors
using MRI (Magnetic Resonance Imaging) of the up-
per airway found that after transition from CAPD
(Continuous Automated Peritoneal Dialysis) to NPD
(Nocturnal Peritoneal Dialysis) the size of the pharynx
increased and the prevalence of OSAS reduced (39). 
cArdiOvAsculAr diseAse
The repeated episodes of obstruction during sleep
cause hypoxia that resemble the ischemia reperfusion
syndrome, sleep fragmentation and negative endotho-
racic pressure, leading finally to the activation of the
autonomous nervous system and to hemodynamic
fluctuations during the episodes of apnea (40). Typ-
ically, 5-7 seconds after each obstructive episode the
cardiac rhythm and the arterial pressure elevate in
contrast to the expected reduction during normal
sleep. It seems that each obstructive episode is a stress-
ful event during a period of time that the parasympa-
thetic nervous system should normally dominate.
Those pathways that are triggered during sleep in
OSAS patients are the ones that lead to the augmented
cardiovascular morbidity and mortality that charac-
terizes the general population. 
Nowadays, many longitudinal studies proved the
strong correlation of OSAS to the augmented risk for
cardiovascular events even after adjusting for age, B-
MI, smoking, systolic and diastolic arterial pressure
(41, 42). Moreover, according to the Sleep Heart
Health Study (43) and the Wisconsin Sleep Cohort
Study (44) the syndrome is strongly related to arterial
hypertension and it is considered as a curable cause
of secondary hypertension (45) and the most common
cause of drug resistant hypertension (46). Cardiac
failure, ischemic heart disease, stroke and arrhythmias
during bedtime are related to OSAS, as well (47, 48). 
In ESRD patients the nocturnal hypoxia has been
related to a non-dipping profile and to concentric left
ventricular hypertrophy and remodeling (49), through
the activation of the autonomous nervous system (50).
Nocturnal hemodialysis seems to be able to reduce
the frequency of apnea and hypoxia episodes and to
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balance the action of sympathetic and parasympathetic
nervous system (51). Furthermore, Abdel-Kader et
al reported that resistant hypertension and severe
OSAS were more prevalent among patients with CKD
and especially among patients undergoing hemodial-
ysis (52), while Jung et al reported strong correlation
of OSAS and severe calcification of coronary arteries
in dialysis patients (28). Nocturnal hypoxia has been
closely related to morbidity and mortality in this pop-
ulation and Zoccali et al reported that even 1% re-
duction of the mean SpO2 during sleep could lead to
an 33% augmentation of fatal and non-fatal cardio-
vascular events risk (53).
treAtment
OSAS is a complex disease and its treatment is com-
plex, as well. According to the American Academy of
Sleep Medicine, its treatment could be medical, be-
havioral and surgical in some cases (9). The thera-
peutic use of positive airway pressure devises (Con-
tinuous positive airway pressure-CPAP, Bilevel positive
airway pressure-BPAP, Autotitrating positive airway
pressure-APAP) that manage to maintain the patency
of the upper airway is considered the treatment of
choice for patients suffering from OSAS. Behavioral
changes on the other hand could be useful and include
body weight reduction, exercise, avoidance of alcohol
and sedatives before sleep and of supine position dur-
ing sleep. In some cases the use of oral devises can
improve the pharynx patency and finally in some cases
the surgical treatment is required in order to deal and
overcome anatomical problems.  
When it comes to ESRD patients with OSAS the
optimal treatment is not still known. Only few studies
have focused on the beneficial effect of the therapeutic
use of CPAP devise (54) or nocturnal oxygen admin-
istration in this population (55), while other authors
focused on the role that the buffer of the hemodialysis
dialysate could play and found that acetate and not
bicarbonate were correlated to central apnea episodes.
Finally, nocturnal dialysis (hemodialysis or peritoneal
dialysis) instead of daytime was investigated and it
seems to benefit ESRD patients suffering from OSAS.
It is believed that its beneficial role is based not only
in the fluid removal during sleep that has already been
described but in the effective clearance of uremic tox-
ins, as well (56). Besides the dysfunction of the upper
airway muscles is the result of neuropathy and my-
opathy that characterizes ESRD patients and is closely
related to uremia (57). For these reasons nocturnal
dialysis is proposed to be an effective treatment for
patients with severe OSAS. 
Transplantation is considered to be another pos-
sible treatment for patients with OSAS and ESRD.
Indeed, there have been reports of patients that were
improved or even cured after transplantation (58-60).
Surprisingly, recently published studies claim that the
prevalence of OSAS in transplanted patients is equal
to the one of ESRD patients under dialysis (15). So
it is believed that transplantation can be a treatment
of the syndrome and at the same time a predisposing
condition to the syndrome occurrence. The trans-
planted patients develop clinical features that resemble
Cushing syndrome, such as weight gain, obesity, ab-
normal fat distribution and metabolic syndrome. Those
clinical features are the result of the immunosuppres-
sive therapy administered to transplanted patients
and could lead to the high prevalence of the syndrome
in this population (15). 
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Σύνδρομο αποφρακτικών απνοιών ύπνου σε ασθενείς με χρόνια νεφρική νόσο
τελικού σταδίου, υπό αιμοκάθαρση
Όλγα Νικητίδου, Νικόλαος Ντόμπρος
ΠερΙληψη: Το Σύνδρομο Αποφρακτικών Απνοιών Ύπνου είναι ένα σύνδρομο το οποίο παρουσιάζει ιδιαίτερα αυξημένο
επιπολασμό μεταξύ των ασθενών με Χρόνια Νεφρική Νόσο (ΧΝΝ) τελικού σταδίου υπό αιμοκάθαρση. Το σύνδρομο
φαίνεται ότι σχετίζεται άμεσα με αύξηση του καρδιαγγειακού κινδύνου τόσο στο γενικό πληθυσμό όσο και στους ασθενείς
με ΧΝΝ. Η αυξημένη καρδιαγγειακή θνητότητα και θνησιμότητα που χαρακτηρίζει τους ασθενείς με ΧΝΝ καθιστά την
έγκαιρη διάγνωση και θεραπεία του συνδρόμου στο συγκεκριμένο πληθυσμό αναγκαία. Η παρούσα βιβλιογραφική ανα-
σκόπηση εστιάζει στην κλινική εικόνα και τη συμπτωματολογία του συνδρόμου στο συγκεκριμένο πληθυσμό καθώς φαίνεται
να είναι διαφορετική από αυτήν που χαρακτηρίζει το γενικό πληθυσμό. Επιπλέον, προσπαθεί να εξηγήσει τους μηχανισμούς
εκείνους που σχετιζόμενοι άμεσα με τη ΧΝΝ ερμηνεύουν το παθογενετικό μηχανισμό του συνδρόμου στους ασθενείς
αυτούς και τη σχέση του με τον αυξημένο καρδιαγγειακό κίνδυνο. Στόχος τελικά της ανασκόπησης αυτής είναι να
κατανοήσουν το ΣΑΑΥ οι νεφρολόγοι, να αντιληφθούν τον αυξημένο του επιπολασμό και την επίπτωση που έχει στους
ασθενείς με ΧΝΝ, να επιτευχθεί έγκαιρη και ακριβής διάγνωση του συνδρόμου και να γίνουν κατανοητές οι θεραπευτικές
επιλογές που ταιριάζουν στον πληθυσμό αυτό. 
Λέξεις κλειδιά: ΣΑΑΥ, ΧΝΝ, Αιμοκάθαρση, καρδιαγγειακός κίνδυνος
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